Spyre Therapeutics, Inc. (SYRE) - Stock Analysis
Last updated: Mar 9, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Six clinical proof‑of‑concept readouts slated for 2026, reported cash runway into 2028 (~$757m cash/marketable securities) and a strong recent 21‑day move (~+26.8% with a one‑day +14% jump) give SYRE a clear event‑driven upside path; momentum traders can exploit this high‑risk setup ahead of Q2 SKYLINE Part A data and subsequent 2026 catalysts.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Minimal leverage • Significant cash burn • Market > book SYRE is asset-rich with minimal leverage and strong liquidity but generates no revenue, large operating losses and negative cash flow while trading at a material premium to book.
Price Behavior
Key Price Behavior Insights: • Above last month SMA • Healthy momentum • Volatile rally/fade Support Level: $35.95–$36.60 (primary); intermediate $38.90 Resistance Level: $44.18 (primary); nearby $43.01–$43.88 Price sits above the last month average (~$38.90) with RSI ~64, signaling short-term bullishness but volatility after a sharp run from $35.95 to $44.18 that failed to hold.
Sentiment & News
Key News Insights: • Cash runway • Multiple readouts • Enrollment ahead Spyre Therapeutics reports strong balance-sheet support with $757M runway into H2 2028, ahead-of-schedule enrollment and multiple Phase 2 readouts planned across SKYLINE/SKYWAY in 2026, and ongoing hiring/retention activity.
AI Summary
SYRE's October financing transforms it from a financing-risk biotech into a well-capitalized, catalyst-driven pick where 2026 Phase‑2 POC readouts (SKYLINE/SKYWAY) and commercial build will determine whether the stock rerates or collapses. Actionable: monitor enrollment/data quality and burn pacing—if multiple POC readouts show clear efficacy/safety, pursue long exposure or partnership talks; if results are ambiguous or require expanded trials, expect sharp downside and potential dilutive financing.
Description
Spyre Therapeutics is a preclinical biotechnology firm developing monoclonal antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. Its lead program is an anti-α4β7 integrin IgG1 candidate, alongside antibody programs against TL1A and IL-23 and several combination regimens currently in preclinical evaluation. The company, incorporated in 2013 and renamed from Aeglea BioTherapeutics in November 2023, is based in Waltham, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 23 | Mar 2 | SYRE | Spyre Therapeutics, Inc. | Six clinical proof‑of‑concept readouts slated for 2026, reported cash runway into 2028 (~$757m cash/marketable securities) and a strong recent 21‑day move (~+26.8% with a one‑day +14% jump) give SYRE a clear event‑driven upside path; momentum traders can exploit this high‑risk setup ahead of Q2 SKYLINE Part A data and subsequent 2026 catalysts. | Closed | -3.8% |